SRPTSarepta Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Sarepta Therapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRPT본 종목 | $2.1B#9 | — | 1.4x#3 | 1.1x#3 | 4.3%#8 | -403.3%#14 | -37.5%#5 | -46.7%#9 | -73.0%#4 | — | 6.9%#9 | — |
| SLS | $2.3B#1 | — | 16.5x#13 | — | -100.0%#12 | 13.0%#5 | — | -19.5%#6 | — | — | 600.6%#1 | — |
| OCUL | $2.2B#2 | — | 4.3x#5 | 42.8x#9 | -18.5%#11 | -37.4%#9 | -519.8%#9 | -51.1%#10 | — | — | -20.4%#13 | — |
| PVLA | $2.2B#3 | — | 10.0x#12 | 50.8x#10 | 65.3%#4 | -139.3%#11 | -90.2%#7 | -19.2%#5 | — | — | 155.8%#2 | — |
| PBH | $2.2B#5 | 12.8x#1 | 1.1x#2 | 2.0x#4 | -4.3%#10 | -11.3%#8 | 28.4%#1 | 9.9%#1 | 5.9%#1 | 4#1 | -28.7%#14 | — |
| GENB | $2.2B#4 | — | 4.8x#7 | — | — | — | — | 0.0%#2 | — | — | — | — |
| BHC | $2.1B#7 | — | — | 0.2x#1 | 6.7%#7 | 441.3%#1 | 17.7%#2 | — | 3.6%#2 | — | -3.5%#10 | 16.7%#1 |
| TRVI | $2.1B#6 | — | 6.6x#9 | — | — | 10.7%#7 | — | -13.3%#4 | — | — | 75.1%#4 | — |
| BHVN | $2.1B#8 | — | 171.4x#15 | — | — | 12.7%#6 | — | -6045.0%#15 | — | — | -10.6%#11 | — |
| NUVB | $2.1B#10 | — | 8.2x#10 | 32.9x#7 | 699.0%#1 | 64.0%#3 | -338.7%#8 | -80.6%#12 | -87.4%#5 | — | 86.8%#3 | — |
| ZBIO | $2.0B#11 | — | 8.3x#11 | 204.6x#11 | 100.0%#3 | -140.6%#12 | -3830.6%#11 | -152.9%#14 | -296.6%#6 | — | 60.9%#6 | — |
| AGIO | $2.0B#12 | — | 1.9x#4 | 36.6x#8 | 48.0%#5 | -161.3%#13 | -873.9%#10 | -40.3%#8 | — | — | -12.8%#12 | — |
| RAPP | $2.0B#13 | — | 4.6x#6 | — | — | -42.4%#10 | — | -26.4%#7 | — | — | 49.2%#7 | — |
| ZYME | $1.9B#14 | — | 23.7x#14 | 18.0x#6 | 38.9%#6 | 33.9%#4 | -87.3%#6 | -100.9%#13 | — | — | 62.9%#5 | — |
| PRGO | $1.9B#15 | — | 0.7x#1 | 0.4x#2 | -2.8%#9 | -729.7%#15 | -26.4%#4 | -56.7%#11 | -20.9%#3 | 4#1 | -32.0%#15 | 8.6%#2 |
| STOK | $1.8B#16 | — | 5.3x#8 | 9.9x#5 | 404.5%#2 | 92.3%#2 | -11.2%#3 | -2.0%#3 | — | — | 20.9%#8 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice